Abstract Library

#4607 BH3-mimetic drugs elicit cell death of neuroendocrine tumours in preclinical models – An emerging therapeutic strategy for NETs

Introduction: There is an unmet clinical need to identify new, effective therapies for patients with neuroendocrine tumours (NETs). Analysis of single-cell expression data revealed that NETs express high levels of the Bcl2 family of antiapoptotic proteins. Therefore, we hypothesised that proapoptotic drugs, such as BH3-mimetics, can induce programmed cell death, i.e., apoptosis, of neuroendocrine cancer cells.

Conference:

Presenting Author: Michael I

Authors: Kulathunga N, Wang Z, Kale J, Lens A, Tsui H,

Keywords: neuroendocrine tumour, BH3-mimetics, Navitoclax, Cabozantinib, patient-derived organoids, apoptosis, 177Lu-Dotatate,

#4469 Therapeutic strategy for pancreatic neuroendocrine tumours: An overview of the TNE West Network (2016-2024)

Introduction: Neuroendocrine tumours (NETs) are relatively rare and often diagnosed at an advanced stage, typically occurring between the ages of 40 and 60. They primarily manifest in the gastrointestinal system, pancreas, bronchi, lungs, thymus, and thyroid.

Conference:

Presenting Author: Bengueddach A

Authors: Bengueddache A, Kehili H, Tidjane A, Tabeti B, Manouni C,

Keywords: neuroendocrine tumour, metastasis, somatostatin analogue, pancreas,

#4232 Aurora kinase A inhibition as a promising therapeutic strategy in ARID1A-mutated neuroendocrine carcinomas: First results of an in vitro and in vivo study

Introduction: Neuroendocrine carcinomas of the gastrointestinal tract (GEP-NEC) are rare but extremely aggressive tumor diseases with a 5-year survival rate of approximately 25%. The inactivating ARID1A mutation can be detected in approximately 40% of cases of GEP-NEC. Previous studies have shown that Aurora kinase A inhibition leads to selective synthetic lethality of ARID1A-deficient colorectal tumor cells.

Conference:

Presenting Author:

Authors: Viol F, Amin T, Sipos B, Fründt T, Smolkova B,

Keywords: Neuroendocrine Carcinoma, Mutation based Therapy, ARID1A, Aurora Kinase A,

#3779 177Lu-DOTATATE in advanced neuroendocrine neoplasms of different locations – Data from 552 cases in the SEPTRALU registry

Introduction: Peptide receptor radionuclide therapy (PRRT) is a therapeutic strategy selected via a marker, somatostatin receptor (SSTRs) expression, with activity in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Its role in tumor sites outside the digestive tract remains unclear.

Conference:

Presenting Author:

Authors: Mitjavila Casanovas M, Carmona-Bayonas A, Bello P, de Matias Leralta J, Garcia Burillo A,

Keywords: 177Lu-DOTATATE, lung, neuroendocrine tumor, PRRT, pheochromocytoma, radionuclide therapy,

#3627 Early prediction of the efficacy of 177Lu-DOTATATE in patients with metastatic neuroendocrine tumors

Introduction: PRRT has a major place in the therapeutic strategy of metastatic NETs. Its efficacy is generally evaluated after four cycles, with no early predictor identified to date. During each PRRT cycle, 177Lu-related gamma emissions can be measured by post-PRRT scintigraphy.

Conference:

Presenting Author:

Authors: Bando-Delaunay A, de Rycke O, Hentic O, Leclerc P, Allouch A,

Keywords: PRRT, scintigraphy, prediction, response,